atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program Jan 12, 2022
MYND Life Sciences Provides Update on Depression Gene Modulation Pathway Patent Application Dec 15, 2021
Novamind Opens New Clinic Focused On Substance Use Disorders, Offering Alternative To Residential Treatment Dec 6, 2021
